IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with…
225 patients now randomized in global Phase 3 clinical trial for IO102-IO103, in combination with…
SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO),…
SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO),…
BOSTON, June 14, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
BOSTON, June 14, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a…
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a…
Expects Extraction and Production Facility to be Operational Before the End of the Third Quarter…
Expects Extraction and Production Facility to be Operational Before the End of the Third Quarter…
ASD-101 protocol submitted to SAHPRA, South Africa’s regulatory agency PAX-101 internally developed supply chain entering…
ASD-101 protocol submitted to SAHPRA, South Africa’s regulatory agency PAX-101 internally developed supply chain entering…
Revenue increased 9% to $11.7 million for the period ended March 31, 2023 (“Q4 FY2023”)…
Revenue increased 9% to $11.7 million for the period ended March 31, 2023 (“Q4 FY2023”)…
Single Use Support, leading provider of fluid management and freeze-thaw logistic solutions for the biopharmaceutical…
Single Use Support, leading provider of fluid management and freeze-thaw logistic solutions for the biopharmaceutical…
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or…
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or…
Participating institutional investors include Bridgewest Group LOS ANGELES, June 14, 2023 (GLOBE NEWSWIRE) — Immix…
Participating institutional investors include Bridgewest Group LOS ANGELES, June 14, 2023 (GLOBE NEWSWIRE) — Immix…
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas…